129 related articles for article (PubMed ID: 17802918)
1. Evaluation of Elisa test for therapeutic monitoring of Nelfinavir in HIV-positive patients.
Uglietti A; Genco F; Donadel E; Rinaldi S; Bastiani E; Maserati R; Meroni V
New Microbiol; 2007 Jul; 30(3):318-20. PubMed ID: 17802918
[TBL] [Abstract][Full Text] [Related]
2. Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression.
Ford J; Cornforth D; Hoggard PG; Cuthbertson Z; Meaden ER; Williams I; Johnson M; Daniels E; Hsyu P; Back DJ; Khoo SH
Antivir Ther; 2004 Feb; 9(1):77-84. PubMed ID: 15040539
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected patients on HAART.
Panhard X; Goujard C; Legrand M; Taburet AM; Diquet B; Mentré F;
Br J Clin Pharmacol; 2005 Oct; 60(4):390-403. PubMed ID: 16187971
[TBL] [Abstract][Full Text] [Related]
4. Pregnancy-related effects on nelfinavir-M8 pharmacokinetics: a population study with 133 women.
Hirt D; Treluyer JM; Jullien V; Firtion G; Chappuy H; Rey E; Pons G; Mandelbrot L; Urien S
Antimicrob Agents Chemother; 2006 Jun; 50(6):2079-86. PubMed ID: 16723569
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous determination of 8 HIV protease inhibitors in human plasma by isocratic high-performance liquid chromatography with combined use of UV and fluorescence detection: amprenavir, indinavir, atazanavir, ritonavir, lopinavir, saquinavir, nelfinavir and M8-nelfinavir metabolite.
Verbesselt R; Van Wijngaerden E; de Hoon J
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Jan; 845(1):51-60. PubMed ID: 16997640
[TBL] [Abstract][Full Text] [Related]
6. Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection.
Benator DA; Weiner MH; Burman WJ; Vernon AA; Zhao ZA; Khan AE; Jones BE; Sandman L; Engle M; Silva-Trigo C; Hsyu PH; Becker MI; Peloquin CA;
Pharmacotherapy; 2007 Jun; 27(6):793-800. PubMed ID: 17542762
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic monitoring of HIV-1 protease inhibitors in the antiretroviral therapy.
Pawiński T; Pulik P; Gralak B; Horban A
Acta Pol Pharm; 2008; 65(1):93-100. PubMed ID: 18536180
[TBL] [Abstract][Full Text] [Related]
8. Clinical benefit of interventions driven by therapeutic drug monitoring.
Rendón A; Núñez M; Jiménez-Nácher I; González de Requena D; González-Lahoz J; Soriano V
HIV Med; 2005 Sep; 6(5):360-5. PubMed ID: 16156885
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of nelfinavir in children: influencing factors and dose implications.
Bergshoeff AS; Fraaij PL; van Rossum AM; Wolfs TF; Geelen SP; de Groot R; Burger DM
Antivir Ther; 2003 Jun; 8(3):215-22. PubMed ID: 12924538
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics and pharmacodynamics of nelfinavir and its active metabolite M8 in HIV-1-infected children.
Crommentuyn KM; Scherpbier HJ; Kuijpers TW; Mathôt RA; Huitema AD; Beijnen JH
Pediatr Infect Dis J; 2006 Jun; 25(6):538-43. PubMed ID: 16732153
[TBL] [Abstract][Full Text] [Related]
11. Maintaining the nelfinavir trough concentration above 0.8 mg/L improves virologic response in HIV-1-infected children.
Burger DM; Bergshoeff AS; De Groot R; Gibb D; Walker S; Tréluyer JM; Hoetelmans RM;
J Pediatr; 2004 Sep; 145(3):403-5. PubMed ID: 15343199
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacokinetics of nelfinavir and its metabolite M8 in human immunodeficiency virus (HIV)-positive and HIV-hepatitis C virus-coinfected subjects.
Regazzi M; Maserati R; Villani P; Cusato M; Zucchi P; Briganti E; Roda R; Sacchelli L; Gatti F; Delle Foglie P; Nardini G; Fabris P; Mori F; Castelli P; Testa L
Antimicrob Agents Chemother; 2005 Feb; 49(2):643-9. PubMed ID: 15673746
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic drug monitoring of saquinavir in patients during protease inhibitor therapy with saquinavir alone or in combination with ritonavir or nelfinavir.
Langmann P; Zilly M; Weissbrich B; Schlör C; Väth T; Richter E; Klinker H
Eur J Med Res; 2000 Feb; 5(2):59-62. PubMed ID: 10720564
[TBL] [Abstract][Full Text] [Related]
14. Protease inhibitor drug levels in the management of human immunodeficiency virus-1 antiretroviral therapy.
Urban AW; Bean P; Aziz D; Graziano FM; Neudeck BL
Int J STD AIDS; 2003 Feb; 14(2):103-8. PubMed ID: 12662388
[TBL] [Abstract][Full Text] [Related]
15. Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV-infected patients.
Duval X; Peytavin G; Albert I; Bénoliel S; Ecobichon JL; Brun-Vézinet F; Mentré F; Leport C; Vildé JL
HIV Med; 2004 Jul; 5(4):307-13. PubMed ID: 15236622
[TBL] [Abstract][Full Text] [Related]
16. Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy.
Reiser M; Salzberger B; Stiepel A; Hoetelmans R; Diehl V; Fätkenheuer G
Eur J Med Res; 1999 Feb; 4(2):54-8. PubMed ID: 10066640
[TBL] [Abstract][Full Text] [Related]
17. Age-related effects on nelfinavir and M8 pharmacokinetics: a population study with 182 children.
Hirt D; Urien S; Jullien V; Firtion G; Rey E; Pons G; Blanche S; Treluyer JM
Antimicrob Agents Chemother; 2006 Mar; 50(3):910-6. PubMed ID: 16495250
[TBL] [Abstract][Full Text] [Related]
18. Anti-HIV agents. Nelfinavir levels during pregnancy.
TreatmentUpdate; 2004; 16(3):5-6. PubMed ID: 17216835
[No Abstract] [Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of nelfinavir administered twice or thrice daily to human immunodeficiency virus type 1-infected children.
Gatti G; Castelli-Gattinara G; Cruciani M; Bernardi S; De Pascalis CR; Pontali E; Papa L; Miletich F; Bassetti D
Clin Infect Dis; 2003 Jun; 36(11):1476-82. PubMed ID: 12766843
[TBL] [Abstract][Full Text] [Related]
20. Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities.
Zhang KE; Wu E; Patick AK; Kerr B; Zorbas M; Lankford A; Kobayashi T; Maeda Y; Shetty B; Webber S
Antimicrob Agents Chemother; 2001 Apr; 45(4):1086-93. PubMed ID: 11257019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
